The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

Novartis’ Kisqali (ribociclib) has been approved by the US Food and Drug Administration (FDA) as part of a combination ...